Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 297-299

  Stewart, H J ^a   Forrest, A P ^b   Everington, D ^c   McDonald, C C ^a   Dewar, J A ^d   Hawkins, R A ^e   Prescott, R J ^a   George, W D ^f  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Information and Statistics Division   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e NHS LOTHIAN   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; Long term tamoxifen; Randomised trial

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030055509     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.356     Document Type: Article

References (3)

1. BREAST CANCER TRIALS COMMITTEE, SCOTTISH CANCER TRIALS OFFICE (MRC). (1987). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet, 2, 171-174.
2. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15.
3. WOLF DM AND JORDAN VC. (1993). A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results in Cancer Research, 127, 23-33.